Market research
MDNA Medicenna Therapeutics Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 2.75
- Dividend yield
- 0.0%
- Beta
- 0.77
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA58490H1073
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 2.75
- Dividend yield
- 0.0%
- Beta
- 0.77
About
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MDNA discussion.
5 years, 4 months ago
Medicenna Therapeutics Corp is currently in a long term downtrend where the price is trading 25.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Medicenna Therapeutics Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 123.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 94.2% to $-4M since the same quarter in the previous year.
Based on the above factors, Medicenna Therapeutics Corp gets an overall score of 1/5.